Celyad Oncology logo

Celyad Oncology(OTC) CLYYF

Market Cap$13.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-97%
1 Year-47%
1 Month+12%
$0.28
+0.00%
+0.00Today
Celyad Oncology last closing stock price
MetricPriceDate
Last closeUSD 0.282026-08-07
Celyad Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+40%USD 0.202026-07-10
1 month+12%USD 0.252026-04-23
3 month+12%USD 0.252026-04-23
Year to date+86.67%USD 0.152025-12-26
1 year-47.17%USD 0.532025-07-28
3 year-53.71%USD 0.602023-07-26
5 year-96.94%USD 9.152021-04-20
Since inception-99.51%USD 56.882014-01-15

Celyad Oncology Financials at a Glance

Market Cap

$13.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€193.00K

Net Income (TTM)

-€3.15M

EPS (TTM)

$0.10

P/E Ratio

2.94

Dividend

$0.00

Beta (Volatility)

-0.91 (Low)

Price

$0.28

Volume

3,868

Open

$0.28

Previous Close

$0.28

Daily Range

$0.28 - $0.28

52-Week Range

$0.15 - $0.41

Estimated Earnings Date

Mar 25, 2027

CLYYF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Celyad Oncology

Celyad Oncology S.A. is a clinical-stage biopharmaceutical company focused on developing innovative chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. The company is advancing several promising candidates, including CYAD-101 and CYAD-211, which are currently in clinical trials.

Products and Services
  • CYAD-101: Allogeneic CAR-T candidate for metastatic colorectal cancer
  • CYAD-211: Allogeneic CAR-T therapy for relapsed/refractory multiple myeloma
  • CYAD-02: Autologous CAR-T candidate for acute myeloid leukemia
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials
  • Collaborations with Novartis and Horizon Discovery enhance research capabilities
  • Potential market expansion as CAR-T therapies gain acceptance
Financial Highlights
  • Recent quarterly revenue of 6,997 EUR, showing growth potential
  • TTM net income margin of 38.33%, indicating operational efficiency
  • Current ratio of 1.92, reflecting strong liquidity position
Celyad Oncology S.A. is positioned in the biotechnology sector, focusing on cutting-edge CAR-T therapies that address significant unmet medical needs in oncology. The company has made substantial progress in its clinical programs, with several candidates advancing through various stages of development. Collaborations with industry leaders like Novartis and Horizon Discovery provide strategic advantages, enhancing the company's research capabilities and market reach. Recent financial performance indicates a revenue increase, alongside a notable net income margin, suggesting effective cost management and operational efficiency. The company's liquidity position, as evidenced by a current ratio above 1, supports its ability to fund ongoing research and development activities. As the CAR-T therapy market continues to evolve, Celyad Oncology S.A. stands to benefit from its innovative pipeline and strategic partnerships, making it an intriguing option for investors interested in the biotechnology space.
AI Generated • Sep 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

Matthew R. Kane, MBA

Website

www.celyad.com

Headquarters

Mont-Saint-Guibert, WA 1435, BE

CLYYF Financials

Key Financial Metrics (TTM)

Gross Margin

29800.00%

Operating Margin

-68728.57%

Net Income Margin

47071.43%

Return on Equity

178.49%

Return on Capital

-294.83%

Return on Assets

141.72%

Earnings Yield

34.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

47.26M

Volume

3.87K

Avg. Volume

62

Financials (TTM)

Gross Profit

€2.06M

Operating Income

-€11.27M

EBITDA

-€10.70M

Operating Cash Flow

-€13.16M

Capital Expenditure

-€118.00K

Free Cash Flow

-€13.16M

Cash & ST Invst.

€120.82K

Total Debt

€24.96K

Celyad Oncology Performance Analysis

Celyad Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 0N/A
20232023-12-31EUR 110,274N/A
20242024-12-31EUR 201,19482.4%
20252025-12-31EUR 23,700-88.2%
Celyad Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-311128.6%
Q22025-06-30-91.9%
Q42025-12-31-50.0%
Q22026-06-30-100.0%
Celyad Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -1.90-5.2%
20232023-12-31EUR -0.36-81.4%
20242024-12-31EUR -0.15-57.2%
20252025-12-31EUR 0.02N/A
Celyad Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3144.1%
Q22025-06-30-32.2%
Q42025-12-31224.0%
Q22026-06-30-124.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€0.00

-100.0%

Gross Profit

-€42.67K

-953.3%

Gross Margin

0.00%

N/A

Market Cap

$13.23MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$778.43K

N/A

Employees

17

N/A

Net Income

-€1.20M

+60.6%

EBITDA

-€1.28M

+54.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€120.82K

-98.3%

Total Debt

€24.96K

-97.2%

Accounts Receivable

€726.91K

-73.9%

Inventory

€24.96K

-98.0%

Long Term Debt

€0.00

-100.0%

Short Term Debt

€24.96K

-84.0%

Return on Assets

1.42%

N/A

Return on Invested Capital

-3.45%

N/A

Free Cash Flow

-€3.62M

+51.4%

Operating Cash Flow

-€3.62M

+47.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KPRXKiora Pharmaceuticals, Inc.
$2.57-1.15%
ALLRAllarity Therapeutics, Inc.
$1.02+5.78%
QNRXQuoin Pharmaceuticals, Ltd.
$4.75-2.66%
PSTVPlus Therapeutics, Inc.
$3.87-3.25%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$118.67+2.36%
BITOProShares Trust - ProShares Bitcoin ETF
$11.26+0.45%
NVDANvidia
$230.67+1.52%
SPCXSpace Exploration Technologies
$150.62+0.93%

Questions About CLYYF

What is the current price of Celyad Oncology?

Celyad Oncology is trading at $0.28 per share.

What is the 52-week range for Celyad Oncology?

Over the past 52 weeks, Celyad Oncology has traded between $0.15 and $0.41.

How much debt does Celyad Oncology have?

As of the most recent reporting period, Celyad Oncology reported total debt of €0.00.

How much cash does Celyad Oncology have on hand?

Celyad Oncology reported €2.01M in cash and cash equivalents in its most recent financial results.

What is Celyad Oncology’s dividend yield?

Celyad Oncology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services